{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:12:53Z","timestamp":1784545973727,"version":"3.55.0"},"reference-count":319,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1053\/j.semnuclmed.2024.07.001","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T01:25:49Z","timestamp":1723166749000},"page":"914-940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Radiolabeled Somatostatin Analogs for Cancer Imaging"],"prefix":"10.1053","volume":"54","author":[{"given":"Aamir K.","family":"Nazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6607-2558","authenticated-orcid":false,"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4068","key":"10.1053\/j.semnuclmed.2024.07.001_bib0001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone","volume":"179","author":"Brazeau","year":"1973","journal-title":"Science"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0002","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41574-018-0020-6","article-title":"The somatostatin-secreting pancreatic \u03b4-cell in health and disease","volume":"14","author":"Rorsman","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0003","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/ijms23031447","article-title":"Role of somatostatin signalling in neuroendocrine tumors","volume":"23","author":"Rogoza","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0004","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1369\/0022155415583535","article-title":"Alpha-, Delta- and PP-cells: Are they the architectural cornerstones of islet structure and co-ordination?","volume":"63","author":"Brereton","year":"2015","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1210\/jcem-48-1-50","article-title":"Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man","volume":"48","author":"Sheppard","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0006","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/j.1582-4934.2010.01125.x","article-title":"Somatostatin receptor biology in neuroendocrine and pituitary tumors: Part1\u2014molecular pathways","volume":"14","author":"Cakir","year":"2010","journal-title":"J Cell Mol Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0007","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3390\/ijms21051682","article-title":"Somatostatin analogs in clinical practice: A review","volume":"21","author":"Gomes-Porras","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1-2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0008","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.mce.2008.02.002","article-title":"Antitumor effects of somatostatin","volume":"286","author":"Pyronnet","year":"2008","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0009","first-page":"601","article-title":"Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives","volume":"18","author":"Woltering","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0010","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3390\/diagnostics12020528","article-title":"Clinical applications of somatostatin receptor (agonist) PET tracers beyond neuroendocrine tumors","volume":"12","author":"Helgebostad","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111226","article-title":"The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors","volume":"527","author":"Vitali","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"9 Suppl 2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0026-0495(90)90217-Z","article-title":"Distribution of somatostatin receptors in normal and tumor tissue","volume":"39","author":"Reubi","year":"1990","journal-title":"Metabolism"},{"issue":"1-3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0960-0760(92)90184-K","article-title":"Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications","volume":"43","author":"Reubi","year":"1992","journal-title":"J Steroid BiochemMol Biol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0014","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3390\/pharmaceutics14071394","article-title":"Comprehensive assessment of somatostatin receptors in various neoplasms: A systematic review","volume":"14","author":"Priyadarshini","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0015","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0016","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1185\/03007990903328959","article-title":"From somatostatin to octreotide LAR: evolution of a somatostatin analogue","volume":"25","author":"Anthony","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0017","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1177\/1078155219839458","article-title":"Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis","volume":"25","author":"Ryan","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0018","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/17474124.2.2.185","article-title":"Vapreotide acetate for the treatment of esophageal variceal bleeding","volume":"2","author":"Cal\u00e8s","year":"2008","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0019","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0020","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrd3788","article-title":"Pasireotide","volume":"11","author":"Feelders","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0021","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0022","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0023","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.chembiol.2006.08.012","article-title":"Design, synthesis, and biological evaluation of somatostatin-based radiopeptides","volume":"13","author":"Ginj","year":"2006","journal-title":"Chem Biol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0024","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.1136.11.3","article-title":"Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy","volume":"11","author":"Ginj","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"8632","key":"10.1053\/j.semnuclmed.2024.07.001_bib0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","article-title":"Localisation of endocrine-related tumors with radioiodinated analogue of somatostatin","volume":"1","author":"Krenning","year":"1989","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0026","first-page":"1501","article-title":"Receptor scintigraphy with a radioiodinated somatostatin analogue: Radiolabeling, purification, biologic activity, and in vivo application in animals","volume":"31","author":"Bakker","year":"1990","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0027","first-page":"1184","article-title":"In vivo use of a radioiodinated somatostatin analogue: Dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man","volume":"32","author":"Bakker","year":"1991","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0028","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0029","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/qjmed\/91.4.295","article-title":"Localization of neuroendocrine tumors with [111In] DTPA-octreotide scintigraphy (Octreoscan): A comparative study with CT and MR imaging","volume":"91","author":"Shi","year":"1998","journal-title":"QJM"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0031","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.2967\/jnumed.110.085753","article-title":"Radiopeptide imaging and therapy in Europe","volume":"52","author":"Ambrosini","year":"2011","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0032","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2007.12.7431","article-title":"Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: New prognostic factors for malignant well-differentiated endocrine tumors","volume":"26","author":"Asnacios","year":"2008","journal-title":"J ClinOncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0033","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s002590000289","article-title":"99mTc-EDDA\/HYNIC-TOC: A new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumors; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives","volume":"27","author":"Decristoforo","year":"2000","journal-title":"Eur J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0034","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/snuc.2001.26205","article-title":"Evolution of Tc-99m in diagnostic radiopharmaceuticals","volume":"31","author":"Banerjee","year":"2001","journal-title":"Semin Nucl Med"},{"issue":"suppl","key":"10.1053\/j.semnuclmed.2024.07.001_bib0035","first-page":"29P","article-title":"New octreotide derivatives labelled with technetium-99m abstracti","volume":"37","author":"Maecke","year":"1996","journal-title":"J NucI Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0036","first-page":"708","article-title":"An intrapatient comparison of 99mTc-EDDA\/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors","volume":"44","author":"Gabriel","year":"2003","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0037","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s002590050556","article-title":"Detection of somatostatin receptor-positive tumors using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: First results in patients and comparison with 111In-DTPA-D-Phe1-octreotide","volume":"27","author":"Bangard","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0038","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3332\/ecancer.2023.1582","article-title":"Clinical validation and diagnostic accuracy of 99mTc-EDDA\/HYNIC-TOC compared to 111In-DTPA-octreotide in patients with neuroendocrine tumors: The LACOG 0214 study","volume":"17","author":"Moriguchi-Jeckel","year":"2023","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0039","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5603\/NMR.2016.0020","article-title":"Evaluation of neuroendocrine tumors with 99mTc-EDDA\/HYNIC TOC","volume":"19","author":"Artiko","year":"2016","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0040","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s00259-013-2501-0","article-title":"Gratifying clinical experience with an indigenously formulated single-vial lyophilized HYNIC-TOC kit at the radiopharmaceutical division of BARC: A pivotal boost for building up a peptide receptor radionuclide therapy programme in an Indian setting","volume":"40","author":"Basu","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0041","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3413\/Nukmed-0851-16-10","article-title":"Incremental value of 99mTc-HYNIC-TOC SPECT\/CT over whole-body planar scintigraphy and SPECT in patients with neuroendocrine tumors","volume":"56","author":"Trogrlic","year":"2017","journal-title":"Nuklearmedizin"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0042","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/MNM.0000000000001416","article-title":"Characterisation of 99mTc EDDA\/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumor uptake using SPECT\/CT standardised uptake values: Initial experience","volume":"42","author":"Reilly","year":"2021","journal-title":"Nucl Med Commun"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0043","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.3390\/cancers14112725","article-title":"The new radiolabeled peptide 99mTcEDDA\/HYNIC-TOC: Is it a feasible choice for diagnosing gastroenteropancreatic NETs?","volume":"14","author":"Gherghe","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0044","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1039\/c3cc38507h","article-title":"The ubiquitous DOTA and its derivatives: The impact of 1,4,7,10-tetraazacyclododecane1,4,7,10-tetraacetic acid on biomedical imaging","volume":"49","author":"Stasiuk","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0045","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00259-004-1697-4","article-title":"68GaDOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5","volume":"32","author":"Wild","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0046","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.122.264860","article-title":"SNMMI procedure standard\/EANM practice guideline for SSTR PET: Imaging neuroendocrine tumors","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0047","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13139-015-0356-y","article-title":"Comparison of diagnostic sensitivity and quantitative indices between (68)Ga-DOTATOC PET\/CT and (111)in-pentetreotide SPECT\/CT in neuroendocrine tumors: A preliminary report","volume":"49","author":"Lee","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0048","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2967\/jnumed.114.144543","article-title":"68Ga-DOTATATE PET\/CT, 99mTc-HYNIC-octreotide SPECT\/CT, and whole-body MR imaging in detection of neuroendocrine tumors: A prospective trial","volume":"55","author":"Etchebehere","year":"2014","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0049","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2478\/raon-2014-0018","article-title":"Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET\/CT and In-111 DTPA octreotide SPECT\/CT","volume":"48","author":"Schreiter","year":"2014","journal-title":"Radiol Oncol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0050","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumors","volume":"34","author":"Buchmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0051","first-page":"905","article-title":"Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: The impact of 99mTc-HYNICTOC SPECT\/SPECT\/CT VERSUS 68Ga-DOTATATE PET\/CT upon clinical management","volume":"42","author":"Kunikowska","year":"2017","journal-title":"ClinNucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0052","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2967\/jnumed.110.076695","article-title":"Radiolabeled bicyclic somatostatin-based analogs: A novel class of potential radiotracers for SPECT\/PET of neuroendocrine tumors","volume":"51","author":"Fani","year":"2010","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0053","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41181-016-0007-3","article-title":"DATATOC: A novel conjugate for kit-type 68Ga labelling of TOC at ambient temperature published correction appears in EJNMMI Radiopharm Chem","volume":"1","author":"Seemann","year":"2017","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0054","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.semnuclmed.2016.04.003","article-title":"Bifunctional gallium-68 chelators: Past, present, and future","volume":"46","author":"Spang","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13550-019-0516-7","article-title":"Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: Clinical translation of [68Ga]Ga-DATA-TOC","volume":"9","author":"Sinnes","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2019.08.006","article-title":"Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumors","volume":"76-77","author":"Gaertner","year":"2019","journal-title":"Nucl Med Biol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0057","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-019-04611-1","article-title":"Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumors: Comparison with [68Ga]Ga-DOTA-NOC PET\/CT","volume":"47","author":"Yadav","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0058","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41181-018-0038-z","article-title":"Production of novel diagnostic radionuclides in small medical cyclotrons","volume":"3","author":"Synowiecki","year":"2018","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0059","first-page":"213","article-title":"64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors","volume":"42","author":"Anderson","year":"2001","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0060","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2967\/jnumed.111.101469","article-title":"Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: First-in-humans study","volume":"53","author":"Pfeifer","year":"2012","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0061","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2967\/jnumed.115.156539","article-title":"64Cu-DOTATATE PET for neuroendocrine tumors: A prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients","volume":"56","author":"Pfeifer","year":"2015","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0062","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2967\/jnumed.116.180430","article-title":"Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET\/CT: A prospective study of 59 patients with neuroendocrine tumors","volume":"58","author":"Johnbeck","year":"2017","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0063","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1039\/C3DT52647J","article-title":"PET imaging of tumors with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate","volume":"43","author":"Paterson","year":"2014","journal-title":"Dalton Trans"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0064","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2967\/jnumed.118.217745","article-title":"64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy","volume":"60","author":"Hicks","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00259-002-1012-1","article-title":"PET imaging of somatostatin receptors: Design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide","volume":"30","author":"Wester","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0066","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.7150\/thno.31806","article-title":"The search for an alternative to [68Ga]Ga-DOTA-TATE in neuroendocrine tumor theranostics: Current state of 18F-labeled somatostatin analog development","volume":"9","author":"Waldmann","year":"2019","journal-title":"Theranostics"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0067","first-page":"566","article-title":"Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: Biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide","volume":"47","author":"Meisetschl\u00e4ger","year":"2006","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0068","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2967\/jnumed.111.088906","article-title":"Targeting somatostatin receptors: preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET","volume":"52","author":"Leyton","year":"2011","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0069","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.bmcl.2011.03.016","article-title":"Synthesis and in vitro evaluation of [18F]fluoroethyl triazole labelled [Tyr3]octreotate analogues using click chemistry","volume":"21","author":"Iddon","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0070","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2967\/jnumed.115.169532","article-title":"Clinical translation of a click-labeled 18F-octreotate radioligand for imaging neuroendocrine tumors","volume":"57","author":"Dubash","year":"2016","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0071","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2967\/jnumed.123.266601","article-title":"Somatostatin receptor imaging with [18F]FET-\u03b2AG-TOCA PET\/CT and [68Ga]Ga-DOTA-Peptide PET\/CT in patients with neuroendocrine tumors: A prospective, phase 2 comparative study","volume":"65","author":"Dubash","year":"2024","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0072","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2967\/jnumed.109.066902","article-title":"A novel facile method of labeling octreotide with (18)F-fluorine","volume":"51","author":"Laverman","year":"2010","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0073","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13277-011-0250-x","article-title":"Optimized labeling of NOTA-conjugated octreotide with F-18","volume":"33","author":"Laverman","year":"2012","journal-title":"Tumor Biol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0074","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/RLU.0000000000002578","article-title":"Clinical application of 18F-AlF-NOTA-Octreotide PET\/CT in combination with 18F-FDG PET\/CT for imaging neuroendocrine neoplasms","volume":"44","author":"Long","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"13","key":"10.1053\/j.semnuclmed.2024.07.001_bib0075","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","article-title":"[18F]AlF-NOTA-octreotide PET imaging: Biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumor patients","volume":"47","author":"Pauwels","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0076","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13550-021-00797-4","article-title":"Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: Comparison with 68Ga-DOTATATE PET\/CT","volume":"11","author":"Hou","year":"2021","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0077","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2967\/jnumed.122.264563","article-title":"18F-AlF-NOTA-octreotide outperforms 68Ga-DOTATATE\/NOC PET in neuroendocrine tumor patients: Results from a prospective, multicenter study","volume":"64","author":"Pauwels","year":"2023","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0078","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/cancers15020439","article-title":"Al[18F]F-NOTA-Octreotide is comparable to [68Ga]Ga-DOTA-TATE for PET\/CT imaging of neuroendocrine tumors in the latin-american population","volume":"15","author":"Haeger","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"36","key":"10.1053\/j.semnuclmed.2024.07.001_bib0079","first-page":"6047","article-title":"18F-labeling of peptides by means of an organosilicon-based fluoride acceptor","volume":"45","author":"Schirrmacher","year":"2006","journal-title":"AngewChemInt Ed Engl"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41181-022-00176-x","article-title":"Favorable SSTR subtype selectivity of SiTATE: New momentum for clinical [18F]SiTATE PET","volume":"7","author":"W\u00e4ngler","year":"2022","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0081","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nucmedbio.2020.07.008","article-title":"Automated production of [18F]SiTATE on a Scintomics GRP\u2122 platform for PET\/CT imaging of neuroendocrine tumors","volume":"88-89","author":"Lindner","year":"2020","journal-title":"Nucl Med Biol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0082","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s00259-019-04501-6","article-title":"Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: A novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors","volume":"47","author":"Ilhan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0083","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1007\/s00259-021-05351-x","article-title":"Dosimetry and optimal scan time of [18F]SiTATE-PET\/CT in patients with neuroendocrine tumors","volume":"48","author":"Beyer","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0084","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s00259-023-06315-z","article-title":"Next-generation PET\/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE","volume":"50","author":"Unterrainer","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0085","first-page":"667","article-title":"PET imaging of meningioma using the novel SSTR-targeting peptide 18F-SiTATE","volume":"46","author":"Unterrainer","year":"2021","journal-title":"ClinNucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0086","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2967\/jnumed.114.137836","article-title":"Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging","volume":"55","author":"Liu","year":"2014","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0087","first-page":"2270","article-title":"First-in-human clinical trial of [18F]AMBF3-TATE for PET imaging of neuroendocrine tumors","volume":"63","author":"Chausse","year":"2022","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0088","first-page":"375","article-title":"Receptor radionuclide therapy of tumors: A road from basic research to clinical applications","volume":"47","author":"Bodei","year":"2006","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0089","first-page":"729","article-title":"Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors","volume":"288","author":"Perrin","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"44","key":"10.1053\/j.semnuclmed.2024.07.001_bib0090","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0091","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2967\/jnumed.111.088922","article-title":"First clinical evidence that imaging with somatostatin receptor antagonists is feasible","volume":"52","author":"Wild","year":"2011","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0092","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2967\/jnumed.111.087999","article-title":"PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: The chelate makes the difference","volume":"52","author":"Fani","year":"2011","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0093","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","article-title":"Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications","volume":"53","author":"Fani","year":"2012","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0094","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2967\/jnumed.117.199760","article-title":"Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: A prospective phase II imaging study","volume":"59","author":"Nicolas","year":"2018","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0095","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2967\/jnumed.119.235093","article-title":"Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: A prospective study","volume":"61","author":"Zhu","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0096","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13550-018-0428-y","article-title":"The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist","volume":"8","author":"Abiraj","year":"2018","journal-title":"EJNMMI Res"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0097","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.semnuclmed.2019.06.002","article-title":"From bench to bedside-the bad berka experience with first-in-human studies","volume":"49","author":"Zhang","year":"2019","journal-title":"Semin Nucl Med"},{"issue":"23","key":"10.1053\/j.semnuclmed.2024.07.001_bib0098","doi-asserted-by":"crossref","first-page":"14590","DOI":"10.3390\/ijms232314590","article-title":"[68Ga]Ga-DATA5m-LM4, a PET radiotracer in the diagnosis of SST2R-positive tumors: Preclinical and first clinical results","volume":"23","author":"Kanellopoulos","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0099","first-page":"86","article-title":"First-in-human study of an optimized, Kit-type, SSTR antagonist 68Ga-DATA5m-LM4 in patients with metastatic neuroendocrine tumors","volume":"62","author":"Zhang","year":"2023","journal-title":"Nuklearmedizin - Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0100","unstructured":"Greifenstein, Lukas, Grus, Tilmann, Klega, Andre, et al. A novel SSTR antagonist [68Ga]Ga-DATA5m-LM4: From bench (radiolabeling) to bedside (first-in-human study). J Nucl Med 63(2):2531, 2022."},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0101","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/ph17030275","article-title":"Head-to-head comparison of SSTR antagonist [68Ga]Ga-DATA5m-LM4 with SSTR agonist [68Ga]Ga-DOTANOC PET\/CT in patients with well differentiated gastroenteropancreatic neuroendocrine tumors: A prospective imaging study","volume":"17","author":"Viswanathan","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0102","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/ph14040300","article-title":"SPECT imaging of SST2-expressing tumors with 99mTc-based somatostatin receptor antagonists: The role of tetraamine, HYNIC, and spacers","volume":"14","author":"Gaonkar","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0103","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nucmedbio.2019.04.004","article-title":"Somatostatin receptor targeting with hydrophilic [99mTc\/186Re]Tc\/Re-tricarbonyl NODAGA and NOTA complexes","volume":"71","author":"Makris","year":"2019","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nucmedbio.2016.12.002","article-title":"Synthesis and evaluation of a 99mTc tricarbonyl-labeled somatostatin receptor-targeting antagonist peptide for imaging of neuroendocrine tumors","volume":"47","author":"Radford","year":"2017","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ph14010019","article-title":"Selection of the first 99mTc-labelled somatostatin receptor subtype 2 antagonist for clinical translation-preclinical assessment of two optimized candidates","volume":"14","author":"Fani","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0106","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/pharmaceutics15030885","article-title":"Development of the 99mTc-Labelled SST2 antagonist TECANT-1 for a first-in-man multicentre clinical study","volume":"15","author":"Novak","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0107","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1007\/s00259-023-06335-9","article-title":"Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor","volume":"50","author":"Opalinska","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0108","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00259-021-05249-8","article-title":"Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE","volume":"48","author":"Xie","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2023.108338","article-title":"Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist","volume":"118-119","author":"Ahenkorah","year":"2023","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0110","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1021\/jm500581d","article-title":"[111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors","volume":"57","author":"Maina","year":"2014","journal-title":"J Med Chem"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0111","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0112","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.113.126177","article-title":"Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net uptake rate for accurate quantification","volume":"55","author":"Velikyan","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0113","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2967\/jnumed.119.236091","article-title":"64Cu-DOTATATE PET\/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: Results of the first U.S. prospective, reader-masked clinical trial","volume":"61","author":"Delpassand","year":"2020","journal-title":"JNucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0114","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","article-title":"Diagnostic performance of Gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumors: A meta-analysis","volume":"42","author":"Treglia","year":"2012","journal-title":"Endocrine"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0115","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","article-title":"Somatostatin receptor PET\/CT in neuroendocrine tumors: update on systematic review and meta-analysis","volume":"40","author":"Geijer","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0116","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0284185113496679","article-title":"Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: A meta-analysis","volume":"55","author":"Yang","year":"2014","journal-title":"Acta Radiol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0117","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/diagnostics10080598","article-title":"Somatostatin receptor PET\/CT imaging for the detection and staging of pancreatic NET: A systematic review and meta-analysis","volume":"10","author":"Bauckneht","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0118","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0119","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2967\/jnumed.116.185587","article-title":"The impact of somatostatin receptor-directed PET\/CT on the management of patients with neuroendocrine tumor: A systematic review and meta-analysis","volume":"58","author":"Barrio","year":"2017","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0121","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2967\/jnumed.120.257808","article-title":"Updates to the appropriate-use criteria for somatostatin receptor PET","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0122","first-page":"188","article-title":"Comparison of gallium-68 somatostatin receptor and 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of neuroendocrine tumors: A systematic review and meta-analysis","volume":"23","author":"Liu","year":"2020","journal-title":"Hell J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0123","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnmt.116.185777","article-title":"MIB-1 index-stratified assessment of dual-tracer PET\/CT with 68Ga-DOTATATE and 18F-FDG and multimodality anatomic imaging in metastatic neuroendocrine tumors of unknown primary in a PRRT workup setting","volume":"45","author":"Sampathirao","year":"2017","journal-title":"J Nucl Med Technol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0124","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1177\/0284185120958412","article-title":"Clinical value of 68Ga-DOTA-SSTR PET\/CT in the diagnosis and detection of neuroendocrine tumors of unknown primary origin: A systematic review and meta-analysis","volume":"62","author":"Ma","year":"2021","journal-title":"Acta Radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00259-008-0944-5","article-title":"Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET\/CT","volume":"36","author":"Miederer","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0126","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.3390\/cancers13143607","article-title":"Target heterogeneity in oncology: The best predictor for differential response to radioligand therapy in neuroendocrine tumors and prostate cancer","volume":"13","author":"Puranik","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0127","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/MNM.0000000000000321","volume":"36","author":"Basu","year":"2015","journal-title":"Nucl Med Commun"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0128","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s11307-019-01328-3","article-title":"The correlation between [68Ga]DOTATATE PET\/CT and cell proliferation in patients with GEP-NENs","volume":"21","author":"Yu","year":"2019","journal-title":"Mol Imaging Biol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0129","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/RLU.0000000000002694","article-title":"Prognostic value of maximum standardized uptake value in 68Ga-somatostatin receptor positron emission tomography for neuroendocrine tumors: A systematic review and meta-analysis","volume":"44","author":"Lee","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0130","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2967\/jnumed.115.162719","article-title":"Prognostic Value of 68Ga-DOTANOC PET\/CT SUVmax in patients with neuroendocrine tumors of the pancreas","volume":"56","author":"Ambrosini","year":"2015","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1053\/j.semnuclmed.2024.07.001_bib0131","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0132","article-title":"Prognostic value of volume-based parameters measured by SSTR PET\/CT in neuroendocrine tumors: A systematic review and meta-analysis","volume":"8","author":"Hou","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"14","key":"10.1053\/j.semnuclmed.2024.07.001_bib0133","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.3390\/cancers15143581","article-title":"Prognostic implications of PET-derived tumor volume and uptake in patients with neuroendocrine tumors","volume":"15","author":"Weber","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0134","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.686235","article-title":"Radiomics-based texture analysis of 68Ga-DOTATATE positron emission tomography and computed tomography images as a prognostic biomarker in adults with neuroendocrine cancers treated with 177Lu-DOTATATE","volume":"11","author":"Atkinson","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0135","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cancers14040984","article-title":"[68Ga]DOTATOC PET\/CT radiomics to predict the response in GEP-NETs undergoing [177Lu]DOTATOC PRRT: The \u201ctheragnomics\u201d concept","volume":"14","author":"Laudicella","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0136","first-page":"75","article-title":"Correlating and combining genomic and proteomic assessment with in vivo molecular functional imaging: Will this be the future roadmap for personalized cancer management?","volume":"31","author":"Basu","year":"2016","journal-title":"Cancer Biother Radiopharm"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0137","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1007\/s00259-014-2805-8","article-title":"Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: Its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT","volume":"41","author":"Basu","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0138","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: Proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0139","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0140","first-page":"178","article-title":"One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: Lessons learnt including practice evolution in an Indian setting","volume":"10","author":"Basu","year":"2020","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0141","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/wjnm.WJNM_62_18","article-title":"Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis","volume":"18","author":"Adnan","year":"2019","journal-title":"World J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0142","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnmt.121.261998","article-title":"Discordance between histopathologic grading and dual-tracer PET\/CT findings in metastatic NETs and outcome of 177Lu-DOTATATE PRRT: Does in vivo molecular PET perform better from the viewpoint of prediction of tumor biology?","volume":"50","author":"Adnan","year":"2022","journal-title":"J Nucl Med Technol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0143","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.semnuclmed.2020.05.004","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors","volume":"50","author":"Basu","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0144","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0146","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0147","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MNM.0b013e32832999c1","article-title":"68Ga-DOTA-NOC: A new PET tracer for evaluating patients with bronchial carcinoid","volume":"30","author":"Ambrosini","year":"2009","journal-title":"Nucl Med Commun"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0148","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00259-013-2659-5","article-title":"Role of 68Ga-DOTATOC PET\/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid","volume":"41","author":"Venkitaraman","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0149","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/MNM.0000000000001248","article-title":"Does 68Ga-DOTA-NOC-PET\/CT impact staging and therapeutic decision making in pulmonary carcinoid tumors?","volume":"41","author":"Purandare","year":"2020","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-022-00900-3","article-title":"Value of [68Ga]Ga-somatostatin receptor PET\/CT in the grading of pulmonary neuroendocrine (carcinoid) tumors and the detection of disseminated disease: Single-centre pathology-based analysis and review of the literature","volume":"12","author":"Deleu","year":"2022","journal-title":"EJNMMI Res"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0151","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","article-title":"A comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors","volume":"50","author":"Kayani","year":"2009","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0152","first-page":"70","article-title":"Evaluation of the role of [18F]FDG-PET\/CT and [68Ga]DOTATOC-PET\/CT in differentiating typical and atypical pulmonary carcinoids","volume":"11","author":"Jindal","year":"2011","journal-title":"Cancer Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0153","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/icvts\/ivz009","article-title":"Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors and interrelationship with histological features","volume":"28","author":"Lococo","year":"2019","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0154","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.3390\/jcm12113719","article-title":"A systematic review on combined [18F]FDG and 68Ga-SSA PET\/CT in pulmonary carcinoid","volume":"12","author":"Prosperi","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2191-219X-1-19","article-title":"Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice","volume":"1","author":"Erlandsson","year":"2011","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0156","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/RLU.0000000000004591","article-title":"Somatostatin receptor-directed PET\/CT for therapeutic decision-making and disease control in patients affected with small cell lung cancer","volume":"48","author":"Serfling","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0157","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/JTO.0b013e318293f051","article-title":"Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients","volume":"8","author":"Sollini","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0158","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/ijc.31771","article-title":"Somatostatin receptor 2 signalling promotes growth and tumor survival in small-cell lung cancer","volume":"144","author":"Lehman","year":"2019","journal-title":"Int J Cancer"},{"issue":"15","key":"10.1053\/j.semnuclmed.2024.07.001_bib0159","doi-asserted-by":"crossref","first-page":"20033","DOI":"10.18632\/oncotarget.7706","article-title":"Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy","volume":"7","author":"Lapa","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0160","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2967\/jnumed.123.265664","article-title":"68Ga-SSO-120 PET for initial staging of small cell lung cancer patients: A single-center retrospective study","volume":"64","author":"Kersting","year":"2023","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0161","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Dingemans","year":"2021","journal-title":"Annals Oncol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0162","first-page":"1441","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl ComprCancNetw"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0163","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","article-title":"Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas","volume":"86","author":"Leijon","year":"2019","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0164","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy","volume":"51","author":"Srirajaskanthan","year":"2010","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0165","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0166","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0167","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0284185118764206","article-title":"68Ga-somatostatin receptor analogs and 18F-FDG PET\/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis","volume":"59","author":"Kan","year":"2018","journal-title":"Acta Radiol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0168","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0169","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1210\/jc.2017-02324","article-title":"18F-FDOPA PET\/CT imaging of MAX-related pheochromocytoma","volume":"103","author":"Ta\u00efeb","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0170","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00259-015-3268-2","article-title":"Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases","volume":"43","author":"Archier","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0171","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13550-023-01056-4","article-title":"[18F]FDOPA PET\/CT is superior to [68Ga]DOTATOC PET\/CT in diagnostic imaging of pheochromocytoma","volume":"13","author":"Iversen","year":"2023","journal-title":"EJNMMI Res"},{"issue":"1-3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0172","first-page":"61","article-title":"Somatostatin receptor gene expression in neuroblastoma","volume":"88","author":"Albers","year":"2000","journal-title":"RegulPept"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0173","first-page":"1","article-title":"Characterization of somatostatin receptors on human neuroblastoma tumors","volume":"5","author":"O'Dorisio","year":"1994","journal-title":"Cell Growth Differ"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0174","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/ajcp\/102.6.752","article-title":"Expression of somatostatin receptors in childhood neuroblastoma","volume":"102","author":"Moertel","year":"1994","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1148\/radiol.11101352","article-title":"Guidelines for imaging and staging of neuroblastic tumors: consensus report from the international neuroblastoma risk group project","volume":"261","author":"Brisse","year":"2011","journal-title":"Radiology"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0176","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00259-018-4070-8","article-title":"Guidelines on nuclear medicine imaging in neuroblastoma","volume":"45","author":"Bar-Sever","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0177","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/sj.bjc.6605621","article-title":"Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: A report for the international neuroblastoma risk group (INRG) task force","volume":"102","author":"Matthay","year":"2010","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0178","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/MNM.0000000000001265","article-title":"68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: Implications for molecular radiotherapy","volume":"41","author":"Gains","year":"2020","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0179","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00259-011-1962-2","article-title":"Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: A clarification","volume":"39","author":"Kroiss","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0180","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/RLU.0000000000002961","article-title":"The complementary role of 68Ga-DOTATATE PET\/CT in neuroblastoma","volume":"45","author":"Telli","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0181","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/RLU.0000000000002539","article-title":"68Ga-DOTA-TATE in neuroblastoma with marrow involvement","volume":"44","author":"Torun","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0182","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MPH.0000000000000411","article-title":"Initial experience with gallium-68 DOTA-octreotate PET\/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma","volume":"38","author":"Kong","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0183","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2967\/jnumed.110.085100","article-title":"177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma","volume":"52","author":"Gains","year":"2011","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0184","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","article-title":"Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors","volume":"51","author":"Menda","year":"2010","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0185","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/jpm11040270","article-title":"Nuclear medicine imaging in neuroblastoma: Current status and new developments","volume":"11","author":"Samim","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0186","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2967\/jnumed.119.232553","article-title":"Diagnosis, treatment response, and prognosis: The role of 18F-DOPA PET\/CT in children affected by neuroblastoma in comparison with 123I-mIBG scan: The first prospective study","volume":"61","author":"Piccardo","year":"2020","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0187","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0188","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0189","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s12020-017-1424-0","article-title":"Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma","volume":"58","author":"Kendler","year":"2017","journal-title":"Endocrine"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0190","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s12020-018-1706-1","article-title":"SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival","volume":"62","author":"de Vries","year":"2018","journal-title":"Endocrine"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0191","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/apm.12584","article-title":"Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis","volume":"124","author":"Herac","year":"2016","journal-title":"APMIS"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0192","first-page":"362","article-title":"Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: A systematic review and a meta-analysis","volume":"16","author":"Treglia","year":"2017","journal-title":"Hormones (Athens)"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0193","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/978-3-642-27994-2_21","article-title":"Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: Our experience and a review of the literature","volume":"194","author":"Treglia","year":"2013","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0194","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/RLU.0000000000002940","article-title":"Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: A network meta-analysis","volume":"45","author":"Lee","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0195","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12149-020-01494-3","article-title":"Clinical impact of 68Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer","volume":"34","author":"Tuncel","year":"2020","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0196","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12020-022-03116-6","article-title":"Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma","volume":"78","author":"Serfling","year":"2022","journal-title":"Endocrine"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0197","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000381062","article-title":"Somatostatin receptors 2A and 5 are expressed in merkel cell carcinoma with no association with disease severity","volume":"101","author":"Gardair","year":"2015","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0198","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jaad.2012.03.018","article-title":"The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma","volume":"67","author":"Colgan","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0199","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/RLU.0b013e31825ae8e7","article-title":"Comparison of 18F-FDG PET\/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma","volume":"37","author":"Lu","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0200","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13550-018-0423-3","article-title":"18F-FDG and 68Ga-somatostatin analogs PET\/CT in patients with Merkel cell carcinoma: A comparison study","volume":"8","author":"Taralli","year":"2018","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0201","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2967\/jnmt.122.264904","article-title":"Peptide receptor radionuclide therapy in merkel cell carcinoma: A comprehensive review","volume":"51","author":"Askari","year":"2023","journal-title":"J Nucl Med Technol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0202","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2967\/jnumed.121.262344","article-title":"Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic merkel cell carcinoma","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0203","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102977","article-title":"Merkel-cell carcinoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up","volume":"9","author":"Lugowska","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0204","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1005961302340","article-title":"A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma","volume":"38","author":"M\u00fcller","year":"1998","journal-title":"J Neurooncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0205","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-03-0083","article-title":"Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging","volume":"10","author":"Fr\u00fchwald","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0206","first-page":"228","article-title":"Safety and accuracy of 68Ga-DOTATOC PET\/CT in children and young adults with solid tumors","volume":"7","author":"Abongwa","year":"2017","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0207","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/RLU.0000000000002021","article-title":"68Ga-DOTANOC PET\/CT in medulloblastoma","volume":"43","author":"Arunraj","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0208","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","article-title":"Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors","volume":"51","author":"Menda","year":"2010","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0209","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"26","key":"10.1053\/j.semnuclmed.2024.07.001_bib0210","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa010839","article-title":"Octreotide therapy for tumor-induced osteomalacia","volume":"345","author":"Seufert","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0211","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/RLU.0000000000000854","article-title":"68Ga DOTATATE PET\/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia","volume":"40","author":"Zhang","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0212","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.2016-2052","article-title":"68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia","volume":"101","author":"El-Maouche","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0213","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/cen.12426","article-title":"Functional imaging in primary tumor-induced osteomalacia: relative performance of FDG PET\/CT vs somatostatin receptor-based functional scans: A series of nine patients","volume":"81","author":"Jadhav","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0214","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/joim.13593","article-title":"Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia","volume":"293","author":"Jan de Beur","year":"2023","journal-title":"J Intern Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0215","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnmt.116.177873","article-title":"177Lu-DOTATATE PRRT in recurrent skull-base phosphaturic mesenchymal tumor causing osteomalacia: A potential application of PRRT beyond neuroendocrine tumors","volume":"44","author":"Basu","year":"2016","journal-title":"J Nucl Med Technol"},{"issue":"Suppl 5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0216","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009 published correction appears in Neuro Oncol. 2013 May;15(5):646-7","volume":"14","author":"Dolecek","year":"2012","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0217","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1148\/radiology.164.2.3496626","article-title":"Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study","volume":"164","author":"Di Chiro","year":"1987","journal-title":"Radiology"},{"issue":"13","key":"10.1053\/j.semnuclmed.2024.07.001_bib0218","first-page":"3455","article-title":"Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization","volume":"54","author":"Reubi","year":"1994","journal-title":"Cancer Res"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0219","first-page":"13185","article-title":"Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance","volume":"8","author":"Silva","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0220","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","article-title":"Detection of cranial meningiomas: Comparison of \u2076\u2078Ga-DOTATOC PET\/CT and contrast-enhanced MRI","volume":"39","author":"Afshar-Oromieh","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0221","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/neuonc\/nou131","article-title":"Comparison of \u2076\u2078Ga-DOTATOC-PET\/CT and PET\/MRI hybrid systems in patients with cranial meningioma: Initial results","volume":"17","author":"Afshar-Oromieh","year":"2015","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0222","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2967\/jnumed.114.149120","article-title":"Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"Rachinger","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0223","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1748-717X-4-56","article-title":"[68Ga]-DOTATOC-PET\/CT for meningioma IMRT treatment planning","volume":"4","author":"Gehler","year":"2009","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0224","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijrobp.2005.12.006","article-title":"Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET","volume":"65","author":"Milker-Zabel","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0225","first-page":"1053","article-title":"PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas","volume":"42","author":"Henze","year":"2001","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0226","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0227","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/neuonc\/now001","article-title":"68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?","volume":"18","author":"Sommerauer","year":"2016","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0228","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.120.249607","article-title":"Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual patient data meta-analysis","volume":"62","author":"Mirian","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0229","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s00259-023-06315-z","article-title":"Next-generation PET\/CT imaging in meningioma\u2014first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE","volume":"50","author":"Unterrainer","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0230","first-page":"8","article-title":"Somatostatin receptors in malignant lymphomas: Targets for radiotherapy?","volume":"45","author":"Dalm","year":"2004","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0231","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00432-016-2220-6","article-title":"Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin","volume":"142","author":"Stollberg","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0232","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1046\/j.1365-2141.2001.02583.x","article-title":"Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: More extended disease identified","volume":"112","author":"Lugtenburg","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0233","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/j.semnuclmed.2005.03.001","article-title":"Initial staging of lymphoma with octreotide and other receptor imaging agents","volume":"35","author":"Ferone","year":"2005","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0234","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1054\/bjoc.2001.2070","article-title":"Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type","volume":"85","author":"Raderer","year":"2001","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0235","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00432-016-2220-6","article-title":"Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin [published correction appears in J Cancer Res Clin Oncol. 2016 Dec 1;:]","volume":"142","author":"Stollberg","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0236","first-page":"273","article-title":"Neuroendocrine differentiation of prostate cancer: A review","volume":"2","author":"Parimi","year":"2014","journal-title":"Am J Clin Exp Urol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0237","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/RLU.0000000000002013","article-title":"Adenocarcinoma prostate with neuroendocrine differentiation: Potential utility of 18F-FDG PET\/CT and 68Ga-DOTANOC PET\/CT Over 68Ga-PSMA PET\/CT","volume":"43","author":"Parida","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0238","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/RLU.0000000000000594","article-title":"Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: Negative on 68Ga-PSMA PET\/CT","volume":"40","author":"Chakraborty","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0239","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.937713","article-title":"Case report: 18F-PSMA PET\/CT scan in castration resistant prostate cancer with aggressive neuroendocrine differentiation","volume":"12","author":"Bergamini","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100801","article-title":"Evaluation of somatostatin and CXCR4 receptor expression in a large set of prostate cancer samples using tissue microarrays and well-characterized monoclonal antibodies","volume":"13","author":"Werner","year":"2020","journal-title":"Transl Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0241","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/039463201002300213","article-title":"Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation","volume":"23","author":"Morichetti","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0242","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RLU.0000000000001424","article-title":"PET\/CT with 68Ga-DOTA-TATE for diagnosis of neuroendocrine: Differentiation in patients with castrate-resistant prostate cancer","volume":"42","author":"Gofrit","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0243","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/j.clgc.2021.01.008","article-title":"Molecular imaging of neuroendocrine differentiation of prostate cancer: A case series","volume":"19","author":"Iravani","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.07.001_bib0244","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/RLU.0000000000001419","article-title":"68Ga-DOTATOC and 68Ga-PSMA PET\/CT unmasked a case of prostate cancer with neuroendocrine differentiation","volume":"41","author":"Chen","year":"2016","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0245","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/diagnostics11030468","article-title":"Neuroendocrine differentiation of prostate cancer is not systematically associated with increased 18F-FDG uptake","volume":"11","author":"Bauckneht","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0246","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/RLU.0000000000002322","article-title":"18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA positive metastatic large cell neuroendocrine prostate tumor","volume":"44","author":"Acar","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0247","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/aja.2010.100","article-title":"Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma","volume":"13","author":"Mazzucchelli","year":"2011","journal-title":"Asian J Androl"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0248","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JCO.2024.42.4_suppl.31","article-title":"Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Pouliot","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0249","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00428-002-0693-y","article-title":"Somatostatin receptors in nasopharyngeal carcinoma","volume":"441","author":"Loh","year":"2002","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0250","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00428-020-02815-7","article-title":"Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma","volume":"477","author":"Tao","year":"2020","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0251","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41467-020-20308-8","article-title":"Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy","volume":"12","author":"Lechner","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0252","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/RLU.0b013e31817dec00","article-title":"Somatostatin receptor scintigraphy in nasopharyngeal carcinoma","volume":"33","author":"Bennink","year":"2008","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0253","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-014-2905-5","article-title":"(68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma","volume":"42","author":"Schartinger","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0254","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/RLU.0000000000001985","article-title":"68Ga-DOTATATE PET\/CT reveals Epstein-Barr virus-associated nasopharyngeal carcinoma in a case of suspected sphenoid wing meningioma","volume":"43","author":"Unterrainer","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0255","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00259-021-05587-7","article-title":"Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography\/computed tomography (PET\/CT) in patients with nasopharyngeal carcinoma","volume":"49","author":"Zhao","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0256","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1007\/s00259-021-05255-w","article-title":"A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET\/MR in patients with nasopharyngeal carcinoma: A prospective study","volume":"48","author":"Qin","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.07.001_bib0257","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1007\/s00259-021-05336-w","article-title":"Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography\/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma","volume":"48","author":"Zhao","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0258","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s11307-022-01748-8","article-title":"[68Ga]Ga-FAPI PET\/CT improves the T staging of patients with newly diagnosed nasopharyngeal carcinoma: A comparison with [18F]F-FDG","volume":"24","author":"Zheng","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0259","article-title":"A head-to-head comparison of [68Ga]Ga-DOTATATE and [68Ga]Ga-FAPI PET\/CT in patients with nasopharyngeal carcinoma: a single-center, prospective study","author":"Zheng","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0261","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00259-015-3058-x","article-title":"Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap","volume":"42","author":"Basu","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0262","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1874471009666160523145005","article-title":"18F-FDG-PET\/CT in patients affected by differentiated thyroid carcinoma with positive thyroglobulin level and negative131I whole body scan. It's value confirmed by a bicentric experience","volume":"9","author":"Bertagna","year":"2016","journal-title":"Curr Radiopharm"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0263","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5603\/NMR.2014.0023","article-title":"The role of 18F-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan","volume":"17","author":"Trybek","year":"2014","journal-title":"Nucl Med Rev"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0264","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/iep.12024","article-title":"Somatostatin receptor expression in thyroid disease","volume":"94","author":"Atkinson","year":"2013","journal-title":"Internat J Exp Pathol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6614-2-1","article-title":"Expression of somatostatin receptor subtypes in human thyroid tumors: The immunohistochemical and molecular biology (RT-PCR) investigation","volume":"2","author":"Pisarek","year":"2009","journal-title":"Thyroid Res"},{"issue":"04","key":"10.1053\/j.semnuclmed.2024.07.001_bib0266","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0029-1243636","article-title":"Somatostatin receptor subtype expression in human thyroid tumors","volume":"42","author":"Klagge","year":"2010","journal-title":"Horm Metab Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0267","first-page":"32","article-title":"Evidence for Somatostatin receptor 2 in thyroid tissue","volume":"138","author":"Druckenthaner","year":"2007","journal-title":"RegulPept"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0268","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1210\/jc.2006-0825","article-title":"99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer","volume":"91","author":"Rodrigues","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0269","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00259-004-1478-0","article-title":"Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value","volume":"31","author":"Stokkel","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0270","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40336-020-00390-0","article-title":"FDG PET\/CT versus somatostatin receptor PET\/CT in TENIS syndrome: a systematic review and meta-analysis","volume":"8","author":"Mourato","year":"2020","journal-title":"Clin Transl Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0271","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/thy.2013.0225","article-title":"Differentiated thyroid cancer: A new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients","volume":"24","author":"Versari","year":"2014","journal-title":"Thyroid,"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0272","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/RLU.0000000000003110","article-title":"Peptide receptor radionuclide therapy in patients with differentiated thyroid cancer","volume":"45","author":"Lee","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0273","first-page":"275","article-title":"Somatostatin receptor imaging and therapy in differentiated thyroid cancer: a ray of hope or the flash before total darkness?","volume":"9","author":"Askari","year":"2021","journal-title":"ClinTransl Imaging"},{"issue":"21","key":"10.1053\/j.semnuclmed.2024.07.001_bib0274","first-page":"6074","article-title":"Somatostatin receptors in human renal cell carcinomas","volume":"52","author":"Reubi","year":"1992","journal-title":"Cancer Res"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.07.001_bib0275","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/00006231-199810000-00005","article-title":"In vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma","volume":"19","author":"Montravers","year":"1998","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0276","first-page":"59","article-title":"[111In-DPTA-D-Phe1]-octreotide scintigraphy in the management of patients with advanced renal cell carcinoma","volume":"14","author":"Edgren","year":"1999","journal-title":"Cancer BiotherRadiopharm"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0277","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/j.clgc.2018.03.011","article-title":"Somatostatin receptor expression in renal cell carcinoma-a new front in the diagnostics and treatment of renal cell carcinoma","volume":"16","author":"H\u00f6\u00f6g","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0278","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/RLU.0000000000001887","article-title":"68Ga-DOTATATE uptake in a soft tissue metastasis from clear cell renal cell cancer","volume":"43","author":"Vamadevan","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0279","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/RLU.0000000000001765","article-title":"68Ga-DOTATATE uptake in solitary pancreatic metastasis from clear cell renal cancer","volume":"42","author":"Vamadevan","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0280","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/wjnm.WJNM_38_17","article-title":"Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature","volume":"17","author":"Nadebaum","year":"2018","journal-title":"World J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0281","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/RLU.0000000000000351","article-title":"Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68Ga DOTATOC PET\/CT: A rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors","volume":"39","author":"Peter","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0282","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/RLU.0000000000001227","article-title":"Metastatic renal cell carcinoma in the thyroid gland and pancreas showing uptake on 68Ga DOTATATE PET\/CT scan","volume":"41","author":"Kanthan","year":"2016","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0283","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/RLU.0000000000004730","article-title":"68 Ga-DOTATOC PET\/CT in pancreatic metastasis from clear cell renal cell carcinoma","volume":"48","author":"Mansour","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0284","first-page":"1723","article-title":"Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells","volume":"17","author":"Zou","year":"2019","journal-title":"Oncol Lett"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0285","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1097\/RLU.0000000000001620","article-title":"68Ga-DOTATATE PET\/CT in nonneuroendocrine tumors","volume":"42","author":"Yamaga","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0286","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3413\/nukmed-0185","article-title":"Incidental detection of breast cancer by 68Ga-DOTATOC-PET\/CT in women suffering from neuroendocrine tumors","volume":"47","author":"Elgeti","year":"2008","journal-title":"Nuklearmedizin"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0287","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/RLU.0000000000003421","article-title":"68Ga-DOTATATE uptake in primary breast cancer","volume":"46","author":"Guirguis","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0288","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/1754-9485.13342","article-title":"Diagnostic value of 68 Ga-DOTATATE PET-CT imaging for staging of ER+ \/PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18 F-FDG PET-CT in a prospective pilot trial","volume":"66","author":"Nguyen","year":"2022","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.07.001_bib0289","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/RLU.0000000000001551","article-title":"Retro-orbital, breast, cardiac, skin, and subcutaneous metastases of neuroendocrine tumor from a tail gut cyst on 68Ga-DOTATATE PET\/CT imaging","volume":"42","author":"Acar","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/RLU.0000000000001463","article-title":"Breast fibroadenoma with increased activity on 68Ga DOTATATE PET\/CT","volume":"42","author":"Papadakis","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.07.001_bib0291","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/RLU.0000000000001266","article-title":"68Ga-DOTATATE breast uptake and expression in breast milk","volume":"41","author":"Forwood","year":"2016","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0292","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rcl.2005.03.003","article-title":"Radionuclide imaging of thoracic malignancies","volume":"43","author":"Goldsmith","year":"2005","journal-title":"Radiol Clin North America"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0293","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1378\/chest.115.1.224","article-title":"The utility of a somatostatin-type receptor binding peptide in the evaluation of solitary pulmonary nodules","volume":"115","author":"Blum","year":"1999","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0294","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1378\/chest.117.5.1232","article-title":"A multi-center trial with a somatostatin analog 99m Tc-depreotide in the evaluation of solitary pulmonary nodules","volume":"117","author":"Blum","year":"2000","journal-title":"Chest"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0295","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/02841850701793777","article-title":"Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer","volume":"49","author":"Axelsson","year":"2008","journal-title":"Acta Radiologica"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0296","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1378\/chest.125.2.494","article-title":"The Utility of 99m Tc depreotide compared With F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer","volume":"125","author":"Kahn","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0297","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s00259-005-1812-1","article-title":"Efficiency of18F-FDG and99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules","volume":"32","author":"Halley","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0298","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00006231-200606000-00006","article-title":"Characterization of radiologically indeterminate lung lesions: 99mTc-depreotide SPECT versus 18F-FDG PET","volume":"27","author":"Ferran","year":"2006","journal-title":"Nucl Med Comm"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0299","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171301","article-title":"68Ga-DOTATATE PET\/CT imaging of indeterminate pulmonary nodules and lung cancer","volume":"12","author":"Walker","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0300","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00259-005-0063-5","article-title":"Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using68Ga-DOTATOC PET and comparison with18F-FDG PET","volume":"33","author":"Dimitrakopoulou-Strauss","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0301","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2967\/jnmt.120.258343","article-title":"Imaging biomarkers in lung cancer with 68Ga-DOTATATE, 18F-Fluoride, and 18F-FDG PET\/CT scans and the theranostics paradigm","volume":"49","author":"Djekidel","year":"2021","journal-title":"J Nucl Med Technol"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0303","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1017\/S0022215112002265","article-title":"Neuroendocrine differentiation in head and neck squamous cell carcinoma","volume":"126","author":"Schartinger","year":"2012","journal-title":"J LaryngolOtol"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0304","article-title":"Incidental finding of squamous cell carcinoma on a 68Ga-DOTATATE PET scan","volume":"9","author":"Mullangi","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0305","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00259-013-2442-7","article-title":"68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma","volume":"40","author":"Schartinger","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0306","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/hed.27243","article-title":"18 F-fludeoxyglucose positron emission computed tomography (18 F-FDG-PET\/CT) versus 68 Ga-DOTATATE-PET\/CT in patients with head and neck cancer: Comparisons and implications for treatment","volume":"45","author":"Patel","year":"2023","journal-title":"Head Neck"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.07.001_bib0307","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s002590050269","article-title":"Somatostatin receptor imaging in intracranial tumors","volume":"25","author":"Schmidt","year":"1998","journal-title":"Eur J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0308","first-page":"537","article-title":"Indium-111-pentetreotide imaging in intra-axial brain tumors: Comparison with thallium-201 SPECT and MRI","volume":"36","author":"Lee","year":"1995","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0309","first-page":"403","article-title":"Somatostatin receptor scintigraphy in central nervous system tumors: Role of blood-brain barrier permeability","volume":"36","author":"Haldemann","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.07.001_bib0310","doi-asserted-by":"crossref","first-page":"25\\","DOI":"10.1186\/s13550-015-0106-2","article-title":"Somatostatin receptor subtype 2 in high-grade gliomas: PET\/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy","volume":"5","author":"Kiviniemi","year":"2015","journal-title":"EJNMMI Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0311","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2967\/jnumed.109.072819","article-title":"Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC","volume":"51","author":"Heute","year":"2010","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0312","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ymeth.2011.09.004","article-title":"Treatment of high-grade glioma with radiolabeled peptides","volume":"55","author":"Waitz","year":"2011","journal-title":"Methods"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0313","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s002680020102","article-title":"Distribution and functional significance of somatostatin receptors in malignant melanoma","volume":"25","author":"Lum","year":"2001","journal-title":"World J Surg"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.07.001_bib0314","first-page":"142","article-title":"Iotandium-111 pentetreotide scintigraphy and CT scans after 3 years in the follow-up of patients with malignant melanoma","volume":"12","author":"Zissimopoulos","year":"2009","journal-title":"Hell J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MNM.0b013e32835ae4ed","article-title":"Comparison between F-18 fluorodeoxyglucose and Ga-68 DOTATOC in metastasized melanoma","volume":"34","author":"Brogsitter","year":"2013","journal-title":"Nucl Med Commun"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.07.001_bib0316","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/0284186X.2012.733075","article-title":"Gastrointestinal stromal tumors (GISTs) express somatostatin receptors and bind radiolabeled somatostatin analogs","volume":"52","author":"Arne","year":"2013","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.07.001_bib0317","first-page":"831","article-title":"Somatostatin receptors in gastrointestinal stromal tumors: New prognostic biomarker and potential therapeutic strategy","volume":"6","author":"Zhao","year":"2014","journal-title":"Am J Transl Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.07.001_bib0318","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S1470-2045(17)30078-5","article-title":"Gastrointestinal stromal tumor detection with somatostatin receptor imaging, 68Ga-HA-DOTATATE PET-CT","volume":"18","author":"Braat","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.07.001_bib0319","first-page":"e1710","article-title":"Somatostatin receptor avidity in gastrointestinal stromal tumors: Theranostic implications of Gallium-68 scan and eligibility for peptide receptor radionuclide therapy","volume":"9","author":"Loaiza-Bonilla","year":"2017","journal-title":"Cureus"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.07.001_bib0320","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13550-021-00747-0","article-title":"The role of [68 Ga]Ga-DOTATATE PET\/CT in wild-type KIT\/PDGFRA gastrointestinal stromal tumors (GIST)","volume":"11","author":"Aloj","year":"2021","journal-title":"EJNMMI Res"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T02:24:05Z","timestamp":1731723845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299824000588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":319,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0001299824000588"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.07.001","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiolabeled Somatostatin Analogs for Cancer Imaging","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}